NanoComposix adds drug manufacturing to services roster

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/greenleaf123)
(Image: Getty/greenleaf123)

Related tags NanoComposix CMO Manufacturing

San Diego, CA-based NanoComposix received its drug manufacturing license which it said will ensure clients are able to use one vendor throughout the product life cycle.

NanoComposix is a nanotechnology development and contract manufacturing organization (CMO) and has been manufacturing nanomaterials for biotech clients under current good manufacturing practices (cGMP) since 2017.

The company recently received its Drug Manufacturing License from the Food and Drug Branch of the State of California Department of Public Health​. 

Dedicated to manufacturing nanomaterial-based medical devices and drugs, the facility includes a qualified ISO 8 cleanroom.

According to the company, “the capability of manufacturing drugs in-house ensures nanoComposix' growing number of clients have the flexibility to utilize one vendor throughout the product life cycle.”

Founder and President Dr. Steve Oldenburg said in a statement: "This opens up a new set of capabilities for our clients and allows us to align with our long-term corporate goal of supplying nanotechnology enabled products from concept through commercialization."

Since 2004, NanoComposix has been providing development, fabrication, processing, and scale-up services to commercialize nanomaterials in several applications, including in vitro​ diagnostics, therapeutics, devices, plasmonic, and preclinical drugs. 

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars